Oncoclínicas (B3: ONCO3) revenue
Oncoclínicas reported revenue of BRL 5,739m for fiscal 2025, 7.8% less than in fiscal 2024 (BRL 6,227m). Since fiscal 2020 its revenue has grown by 182.0%, an average growth of 23.0% a year.
Revenue by fiscal year
| Fiscal year | Revenue | Change | Operating profit | Operating margin |
|---|---|---|---|---|
| 2025 | BRL 5,739m | −7.8% | −BRL 1,990m | −34.7% |
| 2024 | BRL 6,227m | +13.5% | −BRL 119.9m | −1.9% |
| 2023 | BRL 5,489m | +34.3% | BRL 758.0m | 13.8% |
| 2022 | BRL 4,088m | +51.3% | BRL 470.6m | 11.5% |
| 2021 | BRL 2,702m | +32.8% | BRL 177.2m | 6.6% |
| 2020 | BRL 2,035m | — | BRL 19.6m | 1.0% |
The change compares each fiscal year with the one before. Operating margin is operating profit over revenue from the same filing. Figures are in millions of Brazilian reais, except per-share amounts.
Questions about the revenue of Oncoclínicas
- How much revenue did Oncoclínicas make in fiscal 2025?
- Oncoclínicas reported revenue of BRL 5,739m for fiscal 2025, compared with BRL 6,227m in fiscal 2024.
- How much has the revenue of Oncoclínicas grown?
- Between fiscal 2020 and fiscal 2025 it went from BRL 2,035m to BRL 5,739m: 182.0% more, an average growth of 23.0% a year.
- What was the best year for revenue at Oncoclínicas?
- Of its last 6 fiscal years, fiscal 2024, with BRL 6,227m.
- Where do the figures for Oncoclínicas come from?
- From the annual financial statements (DFP) that Oncoclínicas files with the CVM, the Brazilian securities regulator. Each fiscal year links to its filing.
Where each figure comes from
From the annual financial statements (DFP) that Oncoclínicas files with the CVM, the Brazilian securities regulator. The filing for each fiscal year: 2025 · 2024 · 2023 · 2022 · 2021 · 2020. More on Oncoclínicas: the Oncoclínicas page · annual accounts · net income · dividends paid.
More companies from Brazil and the rest of the region: Latin American stocks.
Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.